in earlier the call. by expanding the begin I'll Joe mentioned that X-K Paul. Thanks, on filing
Today, working sales. to that continue have initiatives or agreement pursue we with April lenders asset our our operational announced XX, performance we increase capital and forbearance a while into product certain entered we through improve
performance a As on structure. heavily Joe be made credit overall the multiyear enhancing lens near strengthening improving highlighted, the our and company decisions enterprise with the capital being and profile be through will of of will process, All the transformation value. term focused
While are debt used enable our the credit that confidential, transform reduce seek the business. cash as processes sale additional of to to generate we can proceeds the we and further improvement details be
of under future. in provides continue agreement provide relationship we further evidence The structure with and capital our the have on constructive look forbearance we to updates the forward to further
Emergent core the of progress During advancing the made fourth and improving great business fundamentals quarter, our our products.
operations costs rightsize we derisk improving position. and business and of strategic order sharpened reflect the in financial transition debt. ongoing our business operational revenue, enhancing reduce and our as to concentrate actions to focus reducing strengthen efficiencies continue our These the We and
medical relationship countermeasure Throughout XXXX, and key customers. other government the we a positive very maintained U.S. with
result, continues a reinforce minutes, that, we years variability part XXXX said on essential expand to forecast as past. significant government's of in awards preparedness than planning an evolve. that As more the value in of our as the I'll few contract products has a achieved Having which our
NARCAN Don sales, bring and and industry biopharmaceutical grow be more to expertise health sales pharmaceutical In experience. October, and governments we DeGolyer, industry believe appointed Board, of will prepare advance threats. than the veterans combined to for Neal We years to their products X who with our public continue Fowler valuable partner XX to
Let me progress Slide walk through on core our highlighted making some we're as of across the products, XX.
and treatment heard partnership years This for broader underpinned awareness year. of our FDA, launched the overdose spray Paul, in we've research able company is NARCAN naloxone. you NARCAN in of from programs. state after just demand As ever-increasing and been expanded support the for milestone year, NARCAN last Throughout we as many with to and officially access a strong an that and opioid resulting meet by over-the-counter in development federal expanded and to nasal August the reversal monumental access
NARCAN we the a remain to As we in look our spray near growth expect key to contributor term. nasal ahead,
licensed preparedness BioThrax, the announced supply virus; to response million anthrax and medical of and including the $XX to year the wins million manufacturing $XXX.X with of contract of a across government's of new We scale-up plans. a contract several our a Defense other extend Department countermeasure award treatment the XXXX valued our valued is a also for development million, testament for the products, for $XXX form for a new we've and last BARDA, and XX-year RSDL; existing $XXX.X procurement Department Emergent's CYFENDUS; importance core portfolio contract vaccine. U.S. Defense This option with and U.S. at a contract million already [indiscernible], to at Ebola secured for award contract our to contract U.S. important of
post-exposure achieved we milestones and U.S. received that approvals FDA for R&D received we ACAMXXXX use. Finally, anthrax address for July each many smallpox. this year. We approval TEMBEXA Health important of Canada In our CYFENDUS, XXXX, X-dose prophylactic a regulatory
extend also We would include a that against ACAMXXXX's FDA virus. the supplemental immunization Mpox to indication submitted the to BLA
the by to hear this the expect of We back FDA year. from third quarter
unfold U.S. and efficient an infectious contracts the government's deliver address future range uniquely worldwide. emerging efforts These diseases are the cost-effective to committed these government's high reflect preparedness against potential strengthen in and Emergent is are development threats supporting as level events need positioned maintain to and advances increasing to manner, a preparedness. products to of that, a and frankly, of wide we U.S.
to and In profile XXXX, our structure. initiatives credit capital improve we completed also sale derisk our
As proceeds a you know, to credit generating facility to business, strategic extended save products up to of XXXX, maturity our $XXX $XXX the expense divested million business. May shift annualized on over health we our announced million travel of actions focus implemented and secured our to operating of
on Turning write-offs, to our further We and in the which year to in our was the Adjusted with X. revenue guidance midpoint I'll revenue results. EBITDA by November solid XXXX led quarter, on range had revenue onetime of provided which full shortly. impacted line detail timing provide
margin by gross in NARCAN of quarter of million. of adjusted fourth million, XX, $XX CYFENDUS, Slide total highlights $X.X adjusted negative the million segment in net million loss on EBITDA the $XX total of quarter include: adjusted indicated and driven revenues As and $XXX
from into include initial $XXX deeper on to CYFENDUS items sales Slide durability under MCM revenues, of the shipments on $XX National BARDA sales demand November million, quarterly XX; anthrax deliveries channel driven launch driven NARCAN in interest channels; into OTC $XX Strategic million revenue the BAT; primarily Diving product important from driven and existing U.S. by by MCM on VIIB; the continued option transition revenues and market and we smallpox Stockpile, U.S. including million public the XX contributions also government's demonstrating of in this of provided the by contract bioservices customers. strength million includes $XXX by announced related and NARCAN RSDL consistent the growing of Canada; retail of focus sales sales quarter $XX $XX our of million, continued total of other to reflecting million, the to the product
of sales XX. was $XX million in NARCAN; commercial MCM operating $XX million cost product driven driven of quarter by quarter primarily products in was Turning expenses medical sales sales strong well on Cost to as Slide product of volume other and sales of CYFENDUS the reflecting costs by the countermeasure as which of million, terminations; bioservices project spend $XX to an actions cost restructuring of and write-offs; profitability; NARCAN $XX increased initiatives. key includes improve SG&A million, offset expenses expense onetime to expenses inventory associated related million, R&D by initiatives, of with $XX including reduced supporting taken
we forward. during transparency segments: our quarter fourth to investors move that the and Commercial we Products, Note XX products with now segment will beginning Slide This report With three and results MCM for review that, quarter. performance the move let's of change in XXXX, Services. increased provide as
million XX%. driven BAT. entirely In $XX XX%. the or $XX The was million or gross and revenues $XXX segment, the segment Commercial adjusted anthrax, revenues segment, $XXX were by was MCM of and million RSDL margin gross were million margin In NARCAN, segment comprised adjusted
As gross for negative the adjusted revenues were Services million, and $XX million. segment, $XX segment margin was
our year Full $XXX previously and total the segment at highlight I'll of midpoint range. gross negative end billion million. $X.XX XX% was Slide the at our $XX revenue was guidance. end million XXXX provided margin our of XX, to adjusted net performance. year Shifting was loss Full $XX adjusted in of year full low year adjusted low was our the or also EBITDA million, negative range, guidance Full
of nasal NARCAN Transitioning by was Cost XX, sales which the launch cost influenced million, nasal the Cost products focus spray million, of driven reduction XXXX which late continued our of XXXX. of the existing the channels the by in overhead full was Cost actions announced a product strength as million NARCAN we the structure of spray I'll cost commercial heavily August highlight manufacturing unabsorbed well $XXX the of MCM August over in as volume, to costs. XXXX, counter $XXX and year of first Slide on was primary was bioservices by was mix products half $XXX costs. influenced X. in
was home $XXX expenses. was to the additional $XX expense and business. NARCAN, related R&D included to cost expenses legal SG&A fees prior the including travel of divestiture million the million, marketing restructuring which Chikungunya
the gross revenue to Full XX%, million year to improve adjusted had of Slide spray year, $XX revenue segment reductions write-offs. to And Products on took announced the prior segment year the segment margin volume, segment by in for $XXX influenced MCM cost margin was nasal with and product Moving half and midyear million, August and segment XXXX on adjusted efforts NARCAN restructuring adjusted gross affordability. absorption of up product revenue pricing our by year sales the million, and with we million was The negative in for $XXX versus Commercial margin volume XX. million, mix, first inventory and segment business XX%. line access was prior roughly of full $XXX margin influenced was and of Services reflecting prior MCM costs the X. a $XXX gross sales
I'll our cash XXXX and due was and million sales quarter sheet balance XXXX, timing versus facility. now in touch prior And $XX but in turn in million. year XX of revolving expenditures and credit second liquidity, was under receivable. availability was $XXX negative, cash of $XXX We of full net total of collection million December million including XXXX. as in in XX, liquidity to was Slide $XX cash and were increase The $XXX on and flow to Operating highlights. ended Capital our accounts million. positive of the the it cash the half debt flow select position
guidance, to see please Turning XX. XXXX Slide
continued and expect OTC guidance Canada, revenues product as in as of $XXX in press to channel. public commercial evening, million NARCAN of million the retail total with NARCAN release are million demand to XXXX combined for this we interest in the $X.X strong $XXX channel further $XXX with we announced U.S. sales billion; for our growth providing follows: As full year
MCM product $XXX We're million of sales forecasting to million. $XXX
of procurements we've is BARDA threat the with in As the of level U.S. is in impact now provided funding timing transition priority. that near will government even and magnitude by a primary balancing noted, needs fully and as We strategic that Stockpile. could anthrax that fact recognize previously this remains to licensed, the top the the in particular potential CYFENDUS term. the from Congress this preparedness National Strategic threat procurement multiple
provided As the a outcomes range we've segment. MCM a of for result, potential wide
this States is that procurement We to continue our benefit U.S. of citizens. improve with United the to support stakeholders all government engage capability visibility to needed for the critical
note a serving contracts services MCM consistent continue we and segment our stable, to million, to the million our on products, see RSDL. commitment $XX $XX forecasting our of revenue chemical long-term We're government U.S. to the place have and As customers. final for VIGIV, existing sales plasma BAT decontamination products, under the reflecting in to we
profile profitability to and $XX the reduction segments. of our capacity We're forecasting EBITDA XXXX to our of across expectations Shifting revenue $XXX metrics. of the million, range million utilization reflecting adjusted cost impact our actions,
margin over primarily efforts. reflecting profitability full of XXXX to segment the the level, we're our the total year improvement XX%, XX% XXXX, forecasting an year of impact For adjusted increase full of gross
in range Finally, of QX million we're a $XXX forecasting revenue million. to $XXX
Now back thoughts. now that's final to all I'll call Joe the for for over financial update. the turn some
